NCT02033863Unknown不适用
PrOspective, MultiCenter Study for the Evaluation of PerformanCe of the ArtVentive Medical Group Peripheral EndoLuminal OcclUsion SystemTM in the Treatment of Varicocele or Pelvic Congestion SynDromE - OCCLUDE I
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 试验地点
- 3
- 主要终点
- Safety
研究概览
简要总结
To collect confirmatory data in support of the safety and performance of the ArtVentive Medical Group Endoluminal Occlusion System.
详细描述
Prospective, non-randomized, multi-center confirmatory observational study for the treatment of subjects with the need for vascular occlusion for the following conditions:
- Cohort A: Varicocele arising from the spermatic vein(s) and pampiniform plexus, with or without concomitant diagnosis of infertility or subfertility
- Cohort B: Pelvic varices in females for the treatment of pelvic congestion syndrome (e.g., pelvic venous incompetence).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects aged ≥18 to ≤75 years.
- •Subject with target vessels of 3.0 mm to 12.0 mm in diameter.
- •Subject having indications to undergo embolotherapy consistent with clinical and pre-procedural angiographic assessment for spermatic vein origin varicocele (unilateral and/or bilateral) or pelvic congestion syndrome (pelvic venous incompetence).
- •Subject is able and willing to comply with site standard medical follow-up, including one month follow-up visit.
- •Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the consent form.
排除标准
- •Subject has an active systemic infection.
- •Subject has a known allergy to iodinated contrast for which they cannot be adequately premedicated.
- •Subject has history of stroke within the prior 6 months.
- •Subject has history of myocardial infarction with the prior 3 months.
- •Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L), or on dialysis.
- •Subject has a known coagulopathy or has a bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter, or INR >1.
- •Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g., severe chronic obstructive pulmonary disease, hepatic failure, cardiac disease, autoimmune disorders or conditions of severe immunosuppression).
- •Subjects in whom venography or arteriography is contraindicated.
- •Subjects with known hypersensitivity or contraindication to nickel or nitinol.
- •Subject has a less than one year life expectancy.
- •Subject is pregnant or breastfeeding.
- •Subject with endometriosis or other ovarian / uterine pathology with adhesions that would interfere with the endpoints of this study.
- •Subject with previous pelvic surgical intervention or embolotherapy for varicocele or ovarian varices that would interfere with the endpoints of this study, including but not limited to, recurrent varicocele or ovarian varices.
- •Any clinical evidence that the investigator feels would place the subject at increased risk with the deployment of the device.
- •Subject has planned concomitant procedure at the time of the embolization (e.g., coil embolization, etc.).
- •Subject is participating in another study of a device, medication, biologic, or other agent within 30 days or could, in the opinion of the investigator, impact the results of this study.
- •Subject has other medical, social or psychological problems that in the opinion of the investigator would preclude them from receiving this treatment and the procedures and or participating in evaluations pre- and post-treatment.
结局指标
主要结局
Safety
时间窗: Acute & 30 days
Composite of new-onset major device-related adverse event(s) including device embolization beyond targeted treatment area (not therapeutic indication of embolization), need for emergency surgical intervention of the target vessel, or distal embolization (non-device embolization, e.g., particulate matter / plaque distal to the device) at 30 days.
次要结局
- Pain(Acute & 30 days)
- Recurrent varices(30 days)
- Occlusion(30 days)
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
不适用
Evaluation of Peripheral EOS for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEdingHemorrhageBleedingNCT02033954ArtVentive Medical Group, Inc.40
已完成
不适用
Study to Evaluate Made-to-measure Compression GarmentsLymphedemaNCT04901962BSN Medical GmbH99
已完成
不适用
Performance and Safety of the Surgical Hemostatic Agent "HEMOCOLLAGENE®" in Patients Requiring Oral SurgeryOral HemorrhageNCT05171231Septodont125
尚未招募
不适用
LUTEIN BY SCLERAL IONTOPHORESIS IN PATIENTS WITH STAGE 3 AGE-RELATED MACULAR DEGENERATION (AMD)DML Stage 3NCT06465342OFFHEALTH S.p.A.80
已完成
不适用
Anti-SARS-COV2 Vaccination Study in Lung Cancer PatientsCovid19Lung CancerNCT05009030Fundación GECP794